Recent progress on chikungunya virus research.
Wenxi AnNingning GeYilin CaoJin SunXia JinPublished in: Virologica Sinica (2017)
Chikungunya virus (CHIKV) is an arbovirus transmitted by Aedes mosquitos in tropical and subtropical regions across the world. After decades of sporadic outbreaks, it re-emerged in Africa, Asia, India Ocean and America suddenly, causing major regional epidemics recently and becoming a notable global health problem. Infection by CHIKV results in a spectrum of clinical diseases including an acute self-limiting febrile illness in most individuals, a chronic phase of recurrent join pain in a proportion of patients, and long-term arthralgia for months to years for the unfortunate few. No specific anti-viral drugs or licensed vaccines for CHIKV are available so far. A better understanding of virus-host interactions is essential for the development of therapeutics and vaccines. To this end, we reviewed the existing knowledge on CHIKV's epidemiology, clinical presentation, molecular virology, diagnostic approaches, host immune response, vaccine development, and available animal models. Such a comprehensive overview, we believe, will shed lights on the promises and challenges in CHIKV vaccine development.
Keyphrases
- aedes aegypti
- global health
- immune response
- zika virus
- dengue virus
- end stage renal disease
- ejection fraction
- newly diagnosed
- healthcare
- chronic pain
- sars cov
- public health
- prognostic factors
- liver failure
- climate change
- small molecule
- risk factors
- peritoneal dialysis
- hepatitis b virus
- inflammatory response
- spinal cord injury
- infectious diseases
- spinal cord
- patient reported
- postoperative pain